← FDA DRUG APPROVALS

FDA ANDA · ANDA076737

TESTOSTERONE

Sponsor: ACTAVIS LABS UT INC

APPLICATION
ANDA076737
TYPE
ANDA
ORIGINAL APPROVAL
2006-01-27
LATEST ACTION
2019-06-03
ROUTE
TOPICAL, TRANSDERMAL
DOSAGE FORM
GEL, GEL, METERED
MARKETING STATUS
Prescription

Products

TESTOSTERONEPrescription
TESTOSTERONE 50MG/5GM PACKET · GEL · TRANSDERMAL
TESTOSTERONEPrescription
TESTOSTERONE 12.5MG/1.25GM ACTUATION · GEL, METERED · TRANSDERMAL
TESTOSTERONEPrescription
TESTOSTERONE 25MG/2.5GM PACKET · GEL · TRANSDERMAL

Approval history

2019-06-03Labeling · Supplement 13 · standardAP
2019-06-03Labeling · Supplement 9 · standardAP
2015-11-05REMS · Supplement 6AP
2015-10-28Labeling · Supplement 7 · standardAP
2006-01-27OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →